Match!

Precise predictive and therapeutic strategy for breast cancer

Published on Aug 1, 2018in Future Oncology2.279
路 DOI :10.2217/fon-2018-0277
Ioannis D Kyrochristos3
Estimated H-index: 3
,
Dimitra V. Peristeri + 2 AuthorsDimitrios H Roukos4
Estimated H-index: 4
(Academy of Athens)
Abstract
  • References (25)
  • Citations (0)
馃摉 Papers frequently viewed together
1 Citations
2013
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References25
Newest
#1Amritha Nair (BCM: Baylor College of Medicine)H-Index: 2
#2Hsiang-Ching Chung (BCM: Baylor College of Medicine)H-Index: 1
Last. Thomas F. Westbrook (BCM: Baylor College of Medicine)H-Index: 28
view all 37 authors...
Targeting tyrosine kinase receptors that share the feedback inhibitor PTPN12 leads to broad spectrum therapeutic suppression of triple-negative breast cancer.
10 CitationsSource
#1Joshua D. Cohen (Johns Hopkins University)H-Index: 7
#2Lu Li (Johns Hopkins University)H-Index: 8
Last. Nickolas Papadopoulos (Johns Hopkins University)H-Index: 75
view all 42 authors...
Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities rang...
373 CitationsSource
#1David M. Hyman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 35
#2Sarina Anne Piha-Paul (University of Texas MD Anderson Cancer Center)H-Index: 32
Last. David B. Solit (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 83
view all 47 authors...
In a basket trial design, the efficacy of the pan-HER kinase inhibitor neratinib is tested in patients with 21 different tumour types, and responses are determined by mutation and tissue type, and are restricted to HER2-mutant cancers.
109 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 47
#2Kimberly D. Miller Mph (ACS: American Cancer Society)H-Index: 2
Last. Ahmedin Jemal Dvm (ACS: American Cancer Society)H-Index: 4
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
3,124 CitationsSource
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
4,299 CitationsSource
#1Sara A. Hurvitz (UCLA: University of California, Los Angeles)H-Index: 34
#2Miguel Mart 麓 in (Complutense University of Madrid)H-Index: 57
Last. Dennis J. Slamon (UCLA: University of California, Los Angeles)H-Index: 98
view all 20 authors...
Summary Background HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. Methods We did a rando...
45 CitationsSource
#1M. C. Mart铆n (Complutense University of Madrid)H-Index: 2
#2Frankie Ann Holmes (Texas Oncology)H-Index: 16
Last. Mahmoud CharifH-Index: 1
view all 622 authors...
Summary Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings. Methods In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 years...
102 CitationsSource
#2Abctb Investigators (University of Melbourne)H-Index: 1
#3kConFab (Peter MacCallum Cancer Centre)H-Index: 2
Last. Aocs Investigators (University of Melbourne)H-Index: 1
view all 3 authors...
Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry1. We identified 65 new loci that are associated with overall breast cancer risk...
239 CitationsSource
#1Joshua D. Cohen (Johns Hopkins University)H-Index: 7
#2Ammar A. Javed (Johns Hopkins University)H-Index: 12
Last. Anne Marie Lennon (Johns Hopkins University)H-Index: 29
view all 40 authors...
The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. Here we describe our efforts to develop a noninvasive blood test for the detection of pancreatic ductal adenocarcinoma. We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker. The cohort tested included 221 patients with resectable pancreatic ductal adenocarcinomas and 182 control...
102 CitationsSource
The unmet clinical needs of high relapse and cancer-related death rates are reflected by the poor understanding of the genome-wide mutational landscape and molecular mechanisms orchestrating therapeutic resistance. Emerging potential solutions to this challenge include the exploration of cancer genome dynamic evolution in time and space. Breakthrough next-generation sequencing (NGS) applications including multiregional NGS for intratumor heterogeneity identification, repeated cell-free DNA/circu...
18 CitationsSource
Cited By0
Newest